Novo Nordisk on Tuesday received a broker downgrade, with the analysts arguing that its status as a duopoly in both diabetes and weight loss are under threat.
FlashNews:
Ozempic maker Novo Nordisk gets another downgrade. The end’s in sight for its duopoly status, says TD Cowen.
ROA and and wander Unveil Their Second Collaborative Collection
Hyperliquid’s tokenized futures hit $1.2B as traders bet on oil, stocks
The ‘big brother’ helping Arteta’s Arsenal ‘over the line’
Kaine: Trump calling Iran war an ‘excursion’ is ‘deeply disrespectful’ to service members
Tomás Saraceno and Indigenous communities build art complex in Argentine salt flats
Sweat Decks Simplifies Backyard Spa Construction with Full-Service Design and Installation
CricketOps Launches Operating Platform for the Growing Insect Protein Farming Industry
CricketOps Launches Operating Platform for the Growing Insect Protein Farming Industry
CricketOps Launches Operating Platform for the Growing Insect Protein Farming Industry
CricketOps Launches Operating Platform for the Growing Insect Protein Farming Industry
CricketOps Launches Operating Platform for the Growing Insect Protein Farming Industry
CricketOps Launches Operating Platform for the Growing Insect Protein Farming Industry
CricketOps Launches Operating Platform for the Growing Insect Protein Farming Industry
CricketOps Launches Operating Platform for the Growing Insect Protein Farming Industry
CricketOps Launches Operating Platform for the Growing Insect Protein Farming Industry
CricketOps Launches Operating Platform for the Growing Insect Protein Farming Industry
CricketOps Launches Operating Platform for the Growing Insect Protein Farming Industry
CricketOps Launches Operating Platform for the Growing Insect Protein Farming Industry
Home » Ozempic maker Novo Nordisk gets another downgrade. The end’s in sight for its duopoly status, says TD Cowen.